Horizon Pharma (HZNP) Stock Gains on Raised Guidance
NEW YORK (TheStreet) -- Horizon Pharma (HZNP - Get Report) stock is up by 6.14% to $19.20 in mid-morning trading on Tuesday, after the company raised its full-year 2016 revenue guidance.
The Irish biopharmaceutical company announced on Tuesday that it expects full-year revenue of $1.03 to $1.05 billion, versus its previous projection for revenue between $950 million and $975 million for the year.
Horizon raised its revenue guidance as its acquisition of Crealta Holdings is expected to close this week, the company said in a statement.